Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARED3: SOF/VEL and SOF/VEL/VOX for Hepatitis C in Rwanda
NCT03888729Phase 4Unknown
- Sponsor
- Partners In Health
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir + velpatasvir and sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV) (2 arms), sponsored by Partners In Health. Primary endpoints: Sustained Viral Response 12 weeks after discontinuation and Proportion of participants with new grade 3 or 4 adverse event at 24 weeks. Status: unknown.
02
Drugs
sofosbuvir + velpatasvirsofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03888729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888729.